Lazcluze

News

Survival data back Tagrisso's role in first-line lung cancer

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

News

J&J throws the gauntlet down to AZ with new survival data

New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.

News

EU approves endometrial, lung cancer drugs from GSK and J&J

Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.

News

combination of directions for booted feet, two arrows

J&J says Rybrevant combo has survival edge over Tagrisso

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.

News

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and La

Survival data back Tagrisso's role in first-line lung cancer

J&J throws the gauntlet down to AZ with new survival data

EU approves endometrial, lung cancer drugs from GSK and J&J

J&J says Rybrevant combo has survival edge over Tagrisso

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Lazcluze

Editor's Picks